.png)
MediWound
Enzymatic burn debridement (NexoBrid); BARDA mass-casualty & chemical-burn countermeasure
Latest event found: 2 Apr 2026 · 7 months ago
Vitality Radar
Pillar Analysis
Strategic Assessment
Strategic Vector
MediWound is pursuing a dual-track strategy: commercial expansion of NexoBrid while advancing EscharEx for chronic wounds and developing room-temperature-stable formulations for battlefield and mass-casualty use. Government-funded programs and the Vericel relationship strengthen its medical-countermeasure position, while EMA-identified manufacturing modifications indicate execution risk.
Efficiency Ratio
The company appears resource-efficient, converting a focused enzymatic-therapeutics platform into commercial revenue, clinical development, and substantial non-dilutive government programs, although manufacturing scale-up remains a constraint.
Evidence Signals
Vericel was awarded a ten-year BARDA contract valued at up to $197 million to support NexoBrid procurement, inventory services, potential blast-trauma development, and next-generation manufacturing and formulation capabilities.
- About
- Israeli biopharmaceutical company (HQ Yavne, Israel; Nasdaq: MDWD) specializing in enzymatic tissue-repair therapeutics. Its lead product NexoBrid is an FDA-approved orphan biologic that non-surgically removes eschar (dead tissue) from severe thermal burns in a single ~4-hour application, reducing surgical burden — a decisive advantage in mass-casualty burn events where surgical capacity is the bottleneck. Development and procurement are backed by the US BARDA under contracts valued up to $112M for mass-casualty burn preparedness (product delivered to the US stockpile via partner Vericel), plus a separate BARDA contract up to $43M to adapt NexoBrid to treat sulfur-mustard chemical-warfare skin injuries under the FDA Animal Rule. NexoBrid was deployed for burn casualties in Israel after the October 2023 attacks. Companion product EscharEx targets chronic wounds. Note: biologic/pharma (RX-BIO), outside the earlier device-only scope but among the most defense-credentialed Israeli medical companies.
- Tags
- #burns #debridement #enzymatic #masscasualty #cbrn #sulfurmustard #barda #medicalcountermeasure #rxbio #dualuse